Find the right fit for you - faster
Get tailored insights about working at Perlegen in one quick step.
Perlegen Snapshot
Perlegen deciphers genetic signatures. The biotech research company performs whole genome scans to help drugmakers improve drug safety and efficacy and optimize clinical trials. The company also researches the genetic causes of disease and drug response. Using DNA probe arrays from Affymetrix, which owns some 20% of the firm, Perlegen examines multiple whole genomes at a time, looking for variations (single nucleotide polymorphisms, or SNPs) that are responsible for disease. SNPs and groups of SNPs, known as haplotypes, are also responsible for the response, or lack of one, to a drug. Drugmakers hope to use this information to develop genetically targeted medicines.
